| 2024 |
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy |
Articolo in rivista |
Vai |
| 2024 |
Dissecting the nuances of cancer epigenomics in liquid biopsy |
Nota o commento |
Vai |
| 2023 |
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? |
Articolo in rivista |
Vai |
| 2023 |
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay |
Articolo in rivista |
Vai |
| 2023 |
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
Articolo in rivista |
Vai |
| 2023 |
Network approach in liquidomics landscape |
Articolo in rivista |
Vai |
| 2023 |
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? |
Articolo in rivista |
Vai |
| 2023 |
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study |
Articolo in rivista |
Vai |
| 2023 |
The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors |
Articolo in rivista |
Vai |
| 2023 |
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis |
Review essay (rassegna critica) |
Vai |
| 2023 |
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) |
Articolo in rivista |
Vai |
| 2022 |
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review |
Articolo in rivista |
Vai |
| 2022 |
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible |
Articolo in rivista |
Vai |
| 2022 |
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement |
Articolo in rivista |
Vai |
| 2022 |
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors |
Articolo in rivista |
Vai |
| 2022 |
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study |
Articolo in rivista |
Vai |
| 2022 |
Molecular tumor board |
Capitolo o Saggio |
Vai |
| 2022 |
Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code |
Articolo in rivista |
Vai |
| 2022 |
Liquid biopsy and immunotherapy: is all that glitter gold? |
Capitolo o Saggio |
Vai |
| 2022 |
Liquid biopsy: a right tool in a right context? |
Capitolo o Saggio |
Vai |
| 2022 |
Early detection screening: myth or reality? |
Capitolo o Saggio |
Vai |
| 2022 |
Future perspectives |
Capitolo o Saggio |
Vai |
| 2022 |
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis |
Articolo in rivista |
Vai |
| 2022 |
Current clinically validated applications of liquid biopsy |
Capitolo o Saggio |
Vai |
| 2021 |
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study |
Articolo in rivista |
Vai |
| 2021 |
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies |
Articolo in rivista |
Vai |
| 2021 |
TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: An international performance evaluation study |
Articolo in rivista |
Vai |
| 2021 |
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses |
Articolo in rivista |
Vai |
| 2021 |
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials |
Articolo in rivista |
Vai |
| 2021 |
Cancer of the Thyroid |
Capitolo o Saggio |
Vai |
| 2021 |
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups |
Articolo in rivista |
Vai |
| 2021 |
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma |
Recensione in rivista |
Vai |
| 2021 |
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic |
Articolo in rivista |
Vai |
| 2020 |
KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting |
Articolo in rivista |
Vai |
| 2020 |
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal |
Articolo in rivista |
Vai |
| 2020 |
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score |
Articolo in rivista |
Vai |
| 2020 |
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis |
Articolo in rivista |
Vai |
| 2020 |
Tumor mutational burden on cytological samples: A pilot study |
Articolo in rivista |
Vai |
| 2020 |
The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer |
Review essay (rassegna critica) |
Vai |
| 2019 |
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) |
Review essay (rassegna critica) |
Vai |
| 2019 |
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2018 |
Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer |
Articolo in rivista |
Vai |
| 2018 |
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer |
Articolo in rivista |
Vai |
| 2015 |
Diabetes and cancer: A critical appraisal of the pathogenetic and therapeutic links |
Articolo in rivista |
Vai |
